Immuneering Statistics
Total Valuation
Immuneering has a market cap or net worth of $65.52 million. The enterprise value is $19.10 million.
Important Dates
The next estimated earnings date is Friday, February 28, 2025, before market open.
| Earnings Date | Feb 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Immuneering has 31.05 million shares outstanding. The number of shares has increased by 6.64% in one year.
| Current Share Class | 31.05M |
| Shares Outstanding | 31.05M |
| Shares Change (YoY) | +6.64% |
| Shares Change (QoQ) | +0.64% |
| Owned by Insiders (%) | 27.87% |
| Owned by Institutions (%) | 14.02% |
| Float | 22.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.14 |
| P/TBV Ratio | 1.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.99, with a Debt / Equity ratio of 0.07.
| Current Ratio | 7.99 |
| Quick Ratio | 7.32 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -71.81% and return on invested capital (ROIC) is -45.31%.
| Return on Equity (ROE) | -71.81% |
| Return on Assets (ROA) | -42.35% |
| Return on Capital (ROIC) | -45.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$853,950 |
| Employee Count | 68 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -64.30% in the last 52 weeks. The beta is -0.34, so Immuneering's price volatility has been lower than the market average.
| Beta (5Y) | -0.34 |
| 52-Week Price Change | -64.30% |
| 50-Day Moving Average | 2.04 |
| 200-Day Moving Average | 1.73 |
| Relative Strength Index (RSI) | 51.55 |
| Average Volume (20 Days) | 4,900,359 |
Short Selling Information
The latest short interest is 1.76 million, so 5.65% of the outstanding shares have been sold short.
| Short Interest | 1.76M |
| Short Previous Month | 2.29M |
| Short % of Shares Out | 5.65% |
| Short % of Float | 7.84% |
| Short Ratio (days to cover) | 1.19 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -61.82M |
| Pretax Income | -56.07M |
| Net Income | -58.07M |
| EBITDA | -61.43M |
| EBIT | -61.82M |
| Earnings Per Share (EPS) | -$1.97 |
Full Income StatementBalance Sheet
The company has $50.66 million in cash and $4.24 million in debt, giving a net cash position of $46.42 million or $1.49 per share.
| Cash & Cash Equivalents | 50.66M |
| Total Debt | 4.24M |
| Net Cash | 46.42M |
| Net Cash Per Share | $1.49 |
| Equity (Book Value) | 57.72M |
| Book Value Per Share | 1.86 |
| Working Capital | 48.34M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$52.26 million and capital expenditures -$246,437, giving a free cash flow of -$52.51 million.
| Operating Cash Flow | -52.26M |
| Capital Expenditures | -246,437 |
| Free Cash Flow | -52.51M |
| FCF Per Share | -$1.69 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |